Efficacy and Safety of the Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter Phase 3 Study.
Journal
Annals of surgical oncology
ISSN: 1534-4681
Titre abrégé: Ann Surg Oncol
Pays: United States
ID NLM: 9420840
Informations de publication
Date de publication:
04 May 2024
04 May 2024
Historique:
received:
06
02
2024
accepted:
25
03
2024
medline:
5
5
2024
pubmed:
5
5
2024
entrez:
4
5
2024
Statut:
aheadofprint
Résumé
Uveal melanoma (UM) has a poor prognosis once liver metastases occur. The melphalan/Hepatic Delivery System (melphalan/HDS) is a drug/device combination used for liver-directed treatment of metastatic UM (mUM) patients. The purpose of the FOCUS study was to assess the efficacy and safety of melphalan/HDS in patients with unresectable mUM. Eligible patients with mUM received treatment with melphalan (3.0 mg/kg ideal body weight) once every 6 to 8 weeks for a maximum of six cycles. The primary end point was the objective response rate (ORR). The secondary end points included duration of response (DOR), overall survival (OS), and progression-free survival (PFS). The study enrolled 102 patients with mUM. Treatment was attempted in 95 patients, and 91 patients received treatment. In the treated population (n = 91), the ORR was 36.3 % (95 % confidence interval [CI], 26.44-47.01), including 7.7 % of patients with a complete response. Thus, the study met its primary end point because the lower bound of the 95 % CI for ORR exceeded the upper bound (8.3 %) from the benchmark meta-analysis. The median DOR was 14 months, and the median OS was 20.5 months, with an OS of 80 % at 1 year. The median PFS was 9 months, with a PFS of 65 % at 6 months. The most common serious treatment-emergent adverse events were thrombocytopenia (15.8 %) and neutropenia (10.5 %), treated mostly on an outpatient basis with observation. No treatment-related deaths were observed. Treatment with melphalan/HDS provides a clinically meaningful response rate and demonstrates a favorable benefit-risk profile in patients with unresectable mUM (study funded by Delcath; ClinicalTrials.gov identifier: NCT02678572; EudraCT no. 2015-000417-44).
Sections du résumé
BACKGROUND
BACKGROUND
Uveal melanoma (UM) has a poor prognosis once liver metastases occur. The melphalan/Hepatic Delivery System (melphalan/HDS) is a drug/device combination used for liver-directed treatment of metastatic UM (mUM) patients. The purpose of the FOCUS study was to assess the efficacy and safety of melphalan/HDS in patients with unresectable mUM.
METHODS
METHODS
Eligible patients with mUM received treatment with melphalan (3.0 mg/kg ideal body weight) once every 6 to 8 weeks for a maximum of six cycles. The primary end point was the objective response rate (ORR). The secondary end points included duration of response (DOR), overall survival (OS), and progression-free survival (PFS).
RESULTS
RESULTS
The study enrolled 102 patients with mUM. Treatment was attempted in 95 patients, and 91 patients received treatment. In the treated population (n = 91), the ORR was 36.3 % (95 % confidence interval [CI], 26.44-47.01), including 7.7 % of patients with a complete response. Thus, the study met its primary end point because the lower bound of the 95 % CI for ORR exceeded the upper bound (8.3 %) from the benchmark meta-analysis. The median DOR was 14 months, and the median OS was 20.5 months, with an OS of 80 % at 1 year. The median PFS was 9 months, with a PFS of 65 % at 6 months. The most common serious treatment-emergent adverse events were thrombocytopenia (15.8 %) and neutropenia (10.5 %), treated mostly on an outpatient basis with observation. No treatment-related deaths were observed.
CONCLUSION
CONCLUSIONS
Treatment with melphalan/HDS provides a clinically meaningful response rate and demonstrates a favorable benefit-risk profile in patients with unresectable mUM (study funded by Delcath; ClinicalTrials.gov identifier: NCT02678572; EudraCT no. 2015-000417-44).
Identifiants
pubmed: 38704501
doi: 10.1245/s10434-024-15293-x
pii: 10.1245/s10434-024-15293-x
doi:
Banques de données
ClinicalTrials.gov
['NCT02678572']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. Society of Surgical Oncology.
Références
Carvajal RD, Sacco JJ, Jager MJ, et al. Advances in the clinical management of uveal melanoma. Nat Rev Clin Oncol. 2023;20:99–115.
doi: 10.1038/s41571-022-00714-1
pubmed: 36600005
Rantala ES, Hernberg M, Kivelä TT. Overall survival after treatment for metastatic uveal melanoma: a systematic review and meta-analysis. Melanoma Res. 2019;29:561–8.
doi: 10.1097/CMR.0000000000000575
pubmed: 30664106
pmcid: 6887637
Khoja L, Atenafu EG, Suciu S, et al. Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study. Ann Oncol. 2019;30:1370–80.
doi: 10.1093/annonc/mdz176
pubmed: 31150059
Lane AM, Kim IK, Gragoudas ES. Survival rates in patients after treatment for metastasis from uveal melanoma. JAMA Ophthalmol. 2018;136:981–6.
doi: 10.1001/jamaophthalmol.2018.2466
pubmed: 29955797
pmcid: 6142974
Nathan P, Hassel JC, Rutkowski P, et al. Overall survival benefit with tebentafusp in metastatic uveal melanoma. N Engl J Med. 2021;385:1196–206.
doi: 10.1056/NEJMoa2103485
pubmed: 34551229
Koch EA, Petzold A, Wessely A, et al. Immune checkpoint blockade for metastatic uveal melanoma: patterns of response and survival according to the presence of hepatic and extrahepatic metastasis. Cancers Basel. 2021;13:3359.
doi: 10.3390/cancers13133359
pubmed: 34283061
pmcid: 8268645
Mignard C, Huvier AD, Gillibert A, et al. Efficacy of immunotherapy in patients with metastatic mucosal or uveal melanoma. J Oncol. 2018;2018:1908065.
doi: 10.1155/2018/1908065
pubmed: 30631354
pmcid: 6304636
Najjar YG, Navrazhina K, Ding F, et al. Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study. J Immunother Cancer. 2020;8:e000331.
doi: 10.1136/jitc-2019-000331
pubmed: 32581057
pmcid: 7319717
Algazi AP, Tsai KK, Shoushtari AN, et al. Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies. Cancer. 2016;122:3344–53.
doi: 10.1002/cncr.30258
pubmed: 27533448
Pelster MS, Gruschkus SK, Bassett R, et al. Nivolumab and ipilimumab in metastatic uveal melanoma: results from a single-arm phase II study. J Clin Oncol. 2021;39:599–607.
doi: 10.1200/JCO.20.00605
pubmed: 33125309
Piulats JM, Espinosa E, De La Merino CL, et al. Nivolumab plus ipilimumab for treatment-naïve metastatic uveal melanoma: an open-label, multicenter, phase II trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402). J Clin Oncol. 2021;39:586–98.
doi: 10.1200/JCO.20.00550
pubmed: 33417511
Pham JP, On L, Ardolino L, et al. Efficacy of immune checkpoint inhibition in metastatic uveal melanoma: a systematic review and meta-analysis. Melanoma Res. 2023;33:316–25.
doi: 10.1097/CMR.0000000000000900
pubmed: 37199712
Moy CS, Albert DM, Diener-West M, et al. Cause-specific mortality coding: methods in the Collaborative Ocular Melanoma Study COMS report no. 14. Control Clin Trials. 2001;22:248–62.
doi: 10.1016/S0197-2456(01)00113-1
pubmed: 11384789
National Comprehensive Cancer Network (NCCN 2022). NCCN clinical practice guidelines in oncology for melanoma: uveal. Version 2.2022. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1488 .
Prescribing information for the HEPZATO KIT Hepatic Delivery System. Available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/201848s000lbl.pdf .
Bethlehem MS, Katsarelias D, Bagge RO. Meta-analysis of isolated hepatic perfusion and percutaneous hepatic perfusion as a treatment for uveal melanoma liver metastases. Cancers Basel. 2021;13:4726.
doi: 10.3390/cancers13184726
pubmed: 34572953
pmcid: 8469397
Bagge RO, Nelson A, Shafazand A, et al. Isolated hepatic perfusion with melphalan for patients with isolated uveal melanoma liver metastases: a multicenter, randomized, open-label, phase III trial (the SCANDIUM trial). J Clin Oncol. 2023;41:3042–50.
doi: 10.1200/JCO.22.01705
Modi S, Gibson T, Vigneswaran G, et al. Chemosaturation with percutaneous hepatic perfusion of melphalan for metastatic uveal melanoma. Melanoma Res. 2022;32:103–11.
doi: 10.1097/CMR.0000000000000806
pubmed: 35254333
pmcid: 8893121
Meijer TS, Burgmans MC, de Leede EM, et al. Percutaneous hepatic perfusion with melphalan in patients with unresectable ocular melanoma metastases confined to the liver: a prospective phase II study. Ann Surg Oncol. 2021;28:1130–41.
doi: 10.1245/s10434-020-08741-x
pubmed: 32761328
Burgmans MC, de Leede EM, Martini CH, Kapiteijn E, Vahrmeijer AL, van Erkel AR. Percutaneous isolated hepatic perfusion for the treatment of unresectable liver malignancies. Cardiovasc Intervent Radiol. 2016;39:801–14.
doi: 10.1007/s00270-015-1276-z
pubmed: 26718962
Artzner C, Mossakowski O, Hefferman G, et al. Chemosaturation with percutaneous hepatic perfusion of melphalan for liver-dominant metastatic uveal melanoma: a single center experience. Cancer Imaging. 2019;19:31.
doi: 10.1186/s40644-019-0218-4
pubmed: 31146793
pmcid: 6543599
Dewald CLA, Warnke MM, Brüning R, et al. Percutaneous hepatic perfusion (PHP) with melphalan in liver-dominant metastatic uveal melanoma: the German experience. Cancers Basel. 2022;14:118.
doi: 10.3390/cancers14010118
Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649–55.
doi: 10.1097/00000421-198212000-00014
pubmed: 7165009
Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.
doi: 10.1016/j.ejca.2008.10.026
pubmed: 19097774
Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. Published 28 May 2009 (v4.03: 14 June 2010). U.S. Department of Health and Human Services: National Institutes of Health, National Cancer Institute. Available at https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf .
Edge SB, Byrd DR, Compton CC, et al. (eds). Malignant melanoma of the uvea. In AJCC Cancer Staging Manual. 7th ed. Springer: New York, 2010, pp 547–60.
KIMMTRAK (tebentafusp-tebn) USPI. Immunocore. Available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761228s000lbl.pdf .
Leyvraz S, Piperno-Neumann S, Suciu S, et al. Hepatic intra-arterial versus intravenous fotemustine in patients with liver metastases from uveal melanoma (EORTC 18021): a multicentric randomized trial. Ann Oncol. 2014;25:742–6.
doi: 10.1093/annonc/mdt585
pubmed: 24510314
pmcid: 4433517
Valsecchi ME, Terai M, Eschelman DJ, et al. Double-blinded, randomized phase II study using embolization with or without granulocyte-macrophage colony-stimulating factor in uveal melanoma with hepatic metastases. J Vasc Interv Radiol. 2015;26:523-32.e2.
doi: 10.1016/j.jvir.2014.11.037
pubmed: 25678394
pmcid: 4417549
de Leede EM, Burgmans MC, Meijer TS, et al. Prospective clinical and pharmacological evaluation of the Delcath system’s second-generation (GEN2) hemofiltration system in patients undergoing percutaneous hepatic perfusion with melphalan. Cardiovasc Intervent Radiol. 2017;40:1196–205.
doi: 10.1007/s00270-017-1630-4
pubmed: 28451811
pmcid: 5554291
Tong TML, Samim M, Kapiteijn E, et al. Predictive parameters in patients undergoing percutaneous hepatic perfusion with melphalan for unresectable liver metastases from uveal melanoma: a retrospective pooled analysis. Cardiovasc Intervent Radiol. 2022;45:1304–13.
doi: 10.1007/s00270-022-03225-9
pubmed: 35922562
pmcid: 9458688
Meijer TS, Burgmans MC, Fiocco M, et al. Safety of percutaneous hepatic perfusion with melphalan in patients with unresectable liver metastases from ocular melanoma using the Delcath System’s second-generation hemofiltration system: a prospective non-randomized phase II trial. Cardiovasc Intervent Radiol. 2019;42:841–52.
doi: 10.1007/s00270-019-02177-x
pubmed: 30767147
pmcid: 6502784
Tong TML, Burgmans MC, Speetjens FM, et al. Combining melphalan percutaneous hepatic perfusion with ipilimumab plus nivolumab in advanced uveal melanoma: first safety and efficacy data from the phase Ib part of the Chopin trial. Cardiovasc Intervent Radiol. 2023;46:350–9.
doi: 10.1007/s00270-022-03338-1
pubmed: 36624292